[{"address1": "The Gamma Building", "address2": "Ideongatan 1", "city": "Lund", "zip": "223 70", "country": "Sweden", "phone": "46 4 62 86 85 50", "website": "https://www.bioinvent.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206. The company was incorporated in 1996 and is based in Lund, Sweden.", "fullTimeEmployees": 112, "companyOfficers": [{"maxAge": 1, "name": "Dr. Martin  Welschof Ph.D.", "age": 62, "title": "President & CEO", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 5167000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stefan  Ericsson M.B.A.", "age": 60, "title": "Chief Financial Officer", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Marie  Moores M.Sc., R.G.N.", "title": "Chief Operating Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kristoffer Rudenholm Hansson", "age": 49, "title": "Senior Vice President of Technical Operations", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bj\u00f6rn  Frend\u00e9us", "age": 50, "title": "Chief Scientific Officer", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 2353000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Cecilia  Hofvander", "age": 56, "title": "Senior Director of Investor Relations", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andres  McAllister", "age": 67, "title": "Chief Medical Officer", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ingrid  Teige", "title": "Head of Preclinical Research", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sylvie  Ryckebusch", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ingunn Munch Lindvig", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 1, "compensationRisk": 8, "shareHolderRightsRisk": 1, "overallRisk": 3, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.7, "open": 4.7, "dayLow": 4.7, "dayHigh": 4.7, "regularMarketPreviousClose": 4.7, "regularMarketOpen": 4.7, "regularMarketDayLow": 4.7, "regularMarketDayHigh": 4.7, "beta": 0.33, "volume": 908, "regularMarketVolume": 908, "bid": 3.64, "ask": 4.64, "marketCap": 309280672, "fiftyTwoWeekLow": 4.7, "fiftyTwoWeekHigh": 4.7, "priceToSalesTrailing12Months": 5.8721576, "fiftyDayAverage": 4.7, "twoHundredDayAverage": 4.7, "currency": "USD", "enterpriseValue": -733112512, "floatShares": 32815319, "sharesOutstanding": 65804400, "heldPercentInsiders": 0.1336, "heldPercentInstitutions": 0.54695, "impliedSharesOutstanding": 65804400, "bookValue": 16.678, "priceToBook": 0.28180838, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -383478016, "trailingEps": -0.55, "lastSplitFactor": "1:25", "lastSplitDate": 1607904000, "enterpriseToRevenue": -13.919, "enterpriseToEbitda": 1.745, "SandP52WeekChange": 0.24014747, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "BOVNF", "underlyingSymbol": "BOVNF", "shortName": "BIOINVENT INTERNATIONAL AB", "longName": "BioInvent International AB (publ)", "firstTradeDateEpochUtc": 1378215000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "9df5ac7b-0362-3491-ae86-7ec9a5c811db", "messageBoardId": "finmb_139682", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.7, "recommendationKey": "none", "totalCash": 1061504000, "totalCashPerShare": 16.131, "ebitda": -420004992, "totalDebt": 19111000, "quickRatio": 12.182, "currentRatio": 12.297, "totalRevenue": 52669000, "debtToEquity": 1.741, "revenuePerShare": 0.8, "returnOnAssets": -0.19252001, "returnOnEquity": -0.29798, "freeCashflow": -249511872, "operatingCashflow": -363744000, "revenueGrowth": -0.648, "grossMargins": 1.0, "operatingMargins": -32.16678, "financialCurrency": "SEK", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]